Last reviewed · How we verify
NCT00627315
Prospective Study of Hormone Levels After Bariatric Surgery
trial testing Gastric bypass in Obesity in 236 participants. Completed in 4 November 2018.
4 November 2018
Quick facts
| Lead sponsor | Columbia University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 236 |
| Start date | 17 March 2003 |
| Primary completion | 4 November 2018 |
| Estimated completion | 4 November 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Gastric bypass — full drug profile →
- Gastric banding
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
Columbia University
Who can join
18 and older, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project will study the effects of surgery for obesity on bone metabolism and hormones that regulate appetite.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Roux-en-Y Gastric Bypass Is Associated With Hyperinsulinemia But Not Increased Maximal <i>β</i>-Cell Function.
Georgia A, Asnis MCC, Febres G, Tsang A, et al · · 2019 · cited 6× · PMID 30834358 · DOI 10.1210/js.2018-00213
Verify or expand the search:
- PubMed search for NCT00627315
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Gastric bypass
Trials testing the same drug.
- NCT04469712 — Non-randomized Prospective Comparison Between SASI Bipartition and RYGB · active not recruiting
- NCT05476159 — Indocyanine Green Test in Bariatric Surgery · completed
- NCT03673969 — Mini Gastric Bypass vs Roux enY Gastric Bypass · NA · withdrawn
- NCT00627484 — Changes in Insulin Sensitivity After Weight Loss · completed
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Columbia University trials
Trials by the same sponsor.
- NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
- NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
- NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
- NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00627315 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Columbia University
- Last refreshed: 19 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00627315.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing